Zacks Investment Research downgraded Synthetic Biologics Inc (NYSE:SYN) to Hold in a report released today.
- Updated: October 15, 2016
Just yesterday Synthetic Biologics Inc (NYSE:SYN) traded -3.07% lower at $1.67. Synthetic Biologics Inc’s 50-day moving average is $1.69 and its 200-day moving average is $1.92. The last closing price is down -17.78% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 385,723 shares of SYN traded hands, up from an average trading volume of 332,902
Zacks Investment Research has downgraded Synthetic Biologics Inc (NYSE:SYN) to Hold in a report released on 10/12/2016.
Previously on 8/25/2016, BTIG Research reported on Synthetic Biologics Inc (NYSE:SYN) increased the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 2.11%.
Recent Performance Chart
Synthetic Biologics Inc has 52 week low of $0.93 and a 52 week high of $3.09 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 5 brokers have issued a research note on the company. The average stock price target is $8.40 with 4 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On Synthetic Biologics Inc (NYSE:SYN)
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.